dostarlimab

Key facts

Drug.type

mab

Drug.mab_type

mab

Drug.source

zu

Drug.target

PD-1

Drug.tradename

Jemperli

Drug.MedlinePlus

a621030

Drug.DailyMedID

Dostarlimab

Drug.pregnancy_AU

D

Drug.routes_of_administration

Intravenous

Drug.class

Antineoplastic

Drug.ATC_prefix

L01

Drug.ATC_suffix

FF07

Drug.legal_AU

S4

Drug.legal_CA

Rx-only

Drug.legal_CA_comment

/Schedule D

Drug.legal_US

Rx-only

Drug.legal_EU

Rx-only

Drug.CAS_number

2022215-59-2

via Wikipedia infobox

• PHASE2ACTIVE_NOT_RECRUITING
  Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerMassachusetts General Hospital · NCT04837209
• PHASE2WITHDRAWN
  Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal CancersIbrahim Halil Sahin · NCT06365970
• PHASE3ACTIVE_NOT_RECRUITING
  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerTesaro, Inc. · NCT03602859
• PHASE2ACTIVE_NOT_RECRUITING
  TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver CancerUniversity of Hawaii · NCT03680508
• PHASE2NOT_YET_RECRUITING
  XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) PatientsGruppo Oncologico Italiano di Ricerca Clinica · NCT07381777
• PHASE2RECRUITING
  Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon CancerUniversitaire Ziekenhuizen KU Leuven · NCT06830239

via ClinicalTrials.gov